Cargando…

A patient with maculopapular rash and lichenoid skin damage caused by ponatinib

Tyrosine kinase inhibitors (TKIs) are invaluable for the treatment of patients with chronic myelogenous leukemia. Although TKIs are generally better tolerated than traditional chemotherapy, dermatologic side effects are common and present a significant cause of concern for both patients and physicia...

Descripción completa

Detalles Bibliográficos
Autores principales: Teigen, Ingrid Anna, Sæle, Anna Kristine Myrmel, Reikvam, Håkon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7132818/
https://www.ncbi.nlm.nih.gov/pubmed/32242465
http://dx.doi.org/10.1177/0300060520903660
_version_ 1783517512022884352
author Teigen, Ingrid Anna
Sæle, Anna Kristine Myrmel
Reikvam, Håkon
author_facet Teigen, Ingrid Anna
Sæle, Anna Kristine Myrmel
Reikvam, Håkon
author_sort Teigen, Ingrid Anna
collection PubMed
description Tyrosine kinase inhibitors (TKIs) are invaluable for the treatment of patients with chronic myelogenous leukemia. Although TKIs are generally better tolerated than traditional chemotherapy, dermatologic side effects are common and present a significant cause of concern for both patients and physicians. Ponatinib is a third-generation TKI and the only kinase inhibitor effective in patients with certain BCR-ABL1 mutations, including the T315I mutation. However, ponatinib is associated with an increased risk of serious side effects, and severe cutaneous reactions have increasingly been reported. We present a patient who developed a cutaneous lichenoid eruption following the initiation of ponatinib, which resolved after treatment with a topical retinoid. This case demonstrates that cutaneous side effects caused by ponatinib can be managed relatively easily, allowing patients to continue treatment with ponatinib. This is important considerting the limited alternative treatment approaches available for BCR-ABL1 T315I chronic myelogenous leukemia.
format Online
Article
Text
id pubmed-7132818
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-71328182020-04-13 A patient with maculopapular rash and lichenoid skin damage caused by ponatinib Teigen, Ingrid Anna Sæle, Anna Kristine Myrmel Reikvam, Håkon J Int Med Res Case Report Tyrosine kinase inhibitors (TKIs) are invaluable for the treatment of patients with chronic myelogenous leukemia. Although TKIs are generally better tolerated than traditional chemotherapy, dermatologic side effects are common and present a significant cause of concern for both patients and physicians. Ponatinib is a third-generation TKI and the only kinase inhibitor effective in patients with certain BCR-ABL1 mutations, including the T315I mutation. However, ponatinib is associated with an increased risk of serious side effects, and severe cutaneous reactions have increasingly been reported. We present a patient who developed a cutaneous lichenoid eruption following the initiation of ponatinib, which resolved after treatment with a topical retinoid. This case demonstrates that cutaneous side effects caused by ponatinib can be managed relatively easily, allowing patients to continue treatment with ponatinib. This is important considerting the limited alternative treatment approaches available for BCR-ABL1 T315I chronic myelogenous leukemia. SAGE Publications 2020-04-03 /pmc/articles/PMC7132818/ /pubmed/32242465 http://dx.doi.org/10.1177/0300060520903660 Text en © The Author(s) 2020 https://creativecommons.org/licenses/by-nc/4.0/ Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Case Report
Teigen, Ingrid Anna
Sæle, Anna Kristine Myrmel
Reikvam, Håkon
A patient with maculopapular rash and lichenoid skin damage caused by ponatinib
title A patient with maculopapular rash and lichenoid skin damage caused by ponatinib
title_full A patient with maculopapular rash and lichenoid skin damage caused by ponatinib
title_fullStr A patient with maculopapular rash and lichenoid skin damage caused by ponatinib
title_full_unstemmed A patient with maculopapular rash and lichenoid skin damage caused by ponatinib
title_short A patient with maculopapular rash and lichenoid skin damage caused by ponatinib
title_sort patient with maculopapular rash and lichenoid skin damage caused by ponatinib
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7132818/
https://www.ncbi.nlm.nih.gov/pubmed/32242465
http://dx.doi.org/10.1177/0300060520903660
work_keys_str_mv AT teigeningridanna apatientwithmaculopapularrashandlichenoidskindamagecausedbyponatinib
AT sæleannakristinemyrmel apatientwithmaculopapularrashandlichenoidskindamagecausedbyponatinib
AT reikvamhakon apatientwithmaculopapularrashandlichenoidskindamagecausedbyponatinib
AT teigeningridanna patientwithmaculopapularrashandlichenoidskindamagecausedbyponatinib
AT sæleannakristinemyrmel patientwithmaculopapularrashandlichenoidskindamagecausedbyponatinib
AT reikvamhakon patientwithmaculopapularrashandlichenoidskindamagecausedbyponatinib